Not a med emergency: Generic pharma cos spared from harm
NEW DELHI/HYDERABAD: India’s generic companies are likely to continue in business-as-usual mode as US President Donald Trump’s 100% levy on pharmaceuticals is targeted at branded and patented medicines, but it may also prompt some of them to rethink their playbook.Industry experts told TOI that the country’s largest drugmaker Sun Pharma could face headwinds as its…